NZ508416A - Pharmaceutical compositions comprising benzimidazole derivatives, and the use of these compositions for preventing or treating an allergic reaction associated with increased IgE levels in a mammal or for treating or preventing asthma - Google Patents

Pharmaceutical compositions comprising benzimidazole derivatives, and the use of these compositions for preventing or treating an allergic reaction associated with increased IgE levels in a mammal or for treating or preventing asthma

Info

Publication number
NZ508416A
NZ508416A NZ508416A NZ50841699A NZ508416A NZ 508416 A NZ508416 A NZ 508416A NZ 508416 A NZ508416 A NZ 508416A NZ 50841699 A NZ50841699 A NZ 50841699A NZ 508416 A NZ508416 A NZ 508416A
Authority
NZ
New Zealand
Prior art keywords
received
substituted
intellectual property
property office
ige
Prior art date
Application number
NZ508416A
Other languages
English (en)
Inventor
Michael G Campbell
Michael W Major
Jagadish Sircar
Mark L Richards
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ508416(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of NZ508416A publication Critical patent/NZ508416A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NZ508416A 1998-05-22 1999-05-21 Pharmaceutical compositions comprising benzimidazole derivatives, and the use of these compositions for preventing or treating an allergic reaction associated with increased IgE levels in a mammal or for treating or preventing asthma NZ508416A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011322 WO1999061019A1 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE

Publications (1)

Publication Number Publication Date
NZ508416A true NZ508416A (en) 2004-01-30

Family

ID=22198947

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ508416A NZ508416A (en) 1998-05-22 1999-05-21 Pharmaceutical compositions comprising benzimidazole derivatives, and the use of these compositions for preventing or treating an allergic reaction associated with increased IgE levels in a mammal or for treating or preventing asthma
NZ508413A NZ508413A (en) 1998-05-22 1999-05-21 Benzimidazole analogs as down-regulators of IgE

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ508413A NZ508413A (en) 1998-05-22 1999-05-21 Benzimidazole analogs as down-regulators of IgE

Country Status (22)

Country Link
US (2) US6271390B1 (enExample)
EP (3) EP1079830A1 (enExample)
JP (3) JP2002516274A (enExample)
KR (1) KR100591652B1 (enExample)
CN (4) CN1317965A (enExample)
AT (1) ATE292465T1 (enExample)
AU (3) AU754562B2 (enExample)
BR (3) BR9910642A (enExample)
CA (3) CA2332999A1 (enExample)
CZ (2) CZ20004350A3 (enExample)
DE (1) DE69924607T2 (enExample)
ES (1) ES2241285T3 (enExample)
HU (3) HUP0102550A3 (enExample)
IL (3) IL139827A0 (enExample)
MX (3) MXPA00011422A (enExample)
NO (3) NO20005888L (enExample)
NZ (2) NZ508416A (enExample)
PL (3) PL345560A1 (enExample)
RU (2) RU2236221C2 (enExample)
UA (2) UA67775C2 (enExample)
WO (3) WO1999061019A1 (enExample)
ZA (3) ZA200007754B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
BR9910642A (pt) * 1998-05-22 2001-10-09 Avanir Pharmaceuticals Análogos de benzimidazol como reguladores descendentes de ige
BR9913562A (pt) * 1998-09-11 2001-05-22 Ajinomoto Kk Derivados de benzeno, inibidor de ativação de ap-1 e nf-capa b, inibidor de produção de citoquina inflamatória, inibidor de produção de metaloprotease matricial ou inibidor de aparecimento de fator de adesão de célula inflamatório, e, agente antiinflamatório, anti-reumático, imunossupressor, inibidor de metástase cancerosa, remédio para arterioesclerose e agente antiviral
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
RU2001129155A (ru) * 1999-03-26 2003-08-10 Еро-Сельтик С.А. (Lu) Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале
KR20020064147A (ko) * 1999-07-01 2002-08-07 아지노모토 가부시키가이샤 헤테로사이클릭 화합물 및 이의 의약 용도
EP1211240A4 (en) 1999-09-01 2003-02-12 Ajinomoto Kk BISCYCLOPROPANOCARBOXYLIC ACID AMIDE COMPOUNDS AND MEDICINAL USE THEREOF
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
DE60221804T2 (de) * 2001-03-12 2008-05-15 Avanir Pharmaceuticals, San Diego Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
MXPA04000803A (es) 2001-07-27 2004-05-21 Curis Inc Mediadores de rutas de senalizacion de hedgehog, composiciones y usos relacionados a los mismos.
JP4637481B2 (ja) 2001-10-19 2011-02-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｓ１／ｃｈｋ２阻害剤および癌治療における化学療法または放射線療法の補助剤としての２−フェニルベンズイミダゾールおよびイミダゾ−［４，５］−ピリジン
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
EP2527315B1 (en) 2002-05-31 2014-03-19 Proteotech Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20050239844A1 (en) * 2002-11-02 2005-10-27 Kyung-Lim Lee Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
JP4726235B2 (ja) 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼｃｄｓ１（ｃｈｋ２）インヒビターとしての２−フェニル−ベンズイミダゾールおよび２−フェニル−イミダゾ−‘４，５！−ピリジン誘導体
US20050256179A1 (en) * 2003-08-08 2005-11-17 Sircar Jagadish C Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
SG184700A1 (en) 2004-02-20 2012-10-30 Boehringer Ingelheim Int Viral polymerase inhibitors
KR101168451B1 (ko) * 2004-05-12 2012-07-25 프로테오테크, 인크. 아밀로이드 병 및 시뉴클레인 병의 치료를 위한 치환된 ｎ-아릴 벤즈아미드 및 관련 화합물
CA2572218C (en) 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
US8334290B2 (en) † 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7691902B2 (en) * 2005-12-28 2010-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
JP5734956B2 (ja) 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
AR077060A1 (es) 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
WO2011068821A1 (en) * 2009-12-04 2011-06-09 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
NZ606660A (en) 2010-07-20 2014-11-28 Vestaron Corp Insecticidal triazines and pyrimidines
US8829200B2 (en) 2010-10-29 2014-09-09 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US8772304B2 (en) 2010-11-01 2014-07-08 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
AU2019342102B2 (en) 2018-09-18 2024-10-03 Terns Pharmaceuticals, Inc. Compounds for treating certain leukemias
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
DK0469477T3 (da) * 1990-08-02 1995-12-27 Hoffmann La Roche Antiallergisk kombination
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
DK0607373T3 (da) * 1992-06-15 1997-10-13 Celltech Therapeutics Ltd Trisubstituerede phenylderivater som selektive phosphodiesterase IV-inhibitorer.
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
RU2084451C1 (ru) * 1995-10-17 1997-07-20 Акционерное общество закрытого типа "Алмазный Центр" Способ получения 2-фенилбензимидазола
EP0973513A4 (en) * 1996-10-23 2003-03-19 Zymogenetics Inc COMPILATIONS AND METHOD FOR TREATING BONE DEFICIENCY
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
BR9910642A (pt) * 1998-05-22 2001-10-09 Avanir Pharmaceuticals Análogos de benzimidazol como reguladores descendentes de ige
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
CA2429189A1 (en) * 2000-11-15 2002-05-23 Manugistics Atlanta, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
CA2332999A1 (en) 1999-12-02
EP1077695A2 (en) 2001-02-28
RU2236220C2 (ru) 2004-09-20
EP1077700A1 (en) 2001-02-28
CZ20004350A3 (cs) 2002-02-13
NO20005889L (no) 2001-01-22
CN1317965A (zh) 2001-10-17
EP1077700B1 (en) 2005-04-06
DE69924607D1 (de) 2005-05-12
WO1999061020A1 (en) 1999-12-02
KR20010030179A (ko) 2001-04-16
BR9910640A (pt) 2001-10-30
MXPA00011467A (es) 2002-10-17
NZ508413A (en) 2003-08-29
JP2002516277A (ja) 2002-06-04
WO1999061013A3 (en) 2000-04-06
NO20005887L (no) 2001-01-19
NO20005888L (no) 2001-01-22
UA67775C2 (uk) 2004-07-15
IL139827A0 (en) 2002-02-10
MXPA00011422A (es) 2002-12-13
CN1219510C (zh) 2005-09-21
CZ20004351A3 (cs) 2001-10-17
CA2332985A1 (en) 1999-12-02
EP1079830A1 (en) 2001-03-07
HUP0102128A3 (en) 2002-05-28
ZA200007754B (en) 2001-08-16
ATE292465T1 (de) 2005-04-15
WO1999061013A2 (en) 1999-12-02
HUP0102128A2 (hu) 2002-03-28
IL139828A0 (en) 2002-02-10
BR9910641A (pt) 2001-10-02
IL139826A0 (en) 2002-02-10
AU4312099A (en) 1999-12-13
CN1311675A (zh) 2001-09-05
AU4094299A (en) 1999-12-13
JP2002516276A (ja) 2002-06-04
US6271390B1 (en) 2001-08-07
US6451829B2 (en) 2002-09-17
WO1999061019A1 (en) 1999-12-02
KR100591652B1 (ko) 2006-06-26
PL345952A1 (en) 2002-01-14
MXPA00011470A (es) 2002-10-17
AU754562B2 (en) 2002-11-21
BR9910642A (pt) 2001-10-09
HUP0102550A2 (hu) 2001-10-28
PL345219A1 (en) 2001-12-03
US20020010343A1 (en) 2002-01-24
ES2241285T3 (es) 2005-10-16
HUP0101894A3 (en) 2002-07-29
HUP0102550A3 (en) 2002-11-28
NO20005888D0 (no) 2000-11-21
JP2002516274A (ja) 2002-06-04
NO20005889D0 (no) 2000-11-21
DE69924607T2 (de) 2006-02-02
AU754943B2 (en) 2002-11-28
ZA200007752B (en) 2001-12-05
AU4197899A (en) 1999-12-13
ZA200007753B (en) 2001-07-18
CN1721411A (zh) 2006-01-18
HUP0101894A2 (hu) 2002-02-28
NO20005887D0 (no) 2000-11-21
UA67774C2 (uk) 2004-07-15
CA2332989A1 (en) 1999-12-02
CN1311679A (zh) 2001-09-05
PL345560A1 (en) 2001-12-17
RU2236221C2 (ru) 2004-09-20

Similar Documents

Publication Publication Date Title
EP1077700B1 (en) BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE
US6369091B1 (en) Benzimidazole analogs as down-regulators of IgE
US20030004203A1 (en) Benzimidazole derivatives as modulators of IgE
US20030100582A1 (en) Benzimidazole compounds for regulating IgE
KR100599906B1 (ko) ＩｇＥ의 조절제로서의 벤즈이미다졸 유도체
US7256287B2 (en) Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20040214821A1 (en) Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6303645B1 (en) Benzimidazole derivatives as modulators of IgE
US20020132808A1 (en) Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
EP1555020A2 (en) Benzimidazole derivatives as modulators IgE
HK1035326A1 (en) Benzimidazole derivatives as modulators of ige
HK1035326B (en) Benzimidazole derivatives as modulators of ige
AU2003201363B2 (en) Benzimidazole analogs as down-regulators of IgE

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)